Dr Reddy’s CEO On Payer Dynamics, China Commitment And Disruption

 
• By Anju Ghangurde
  
Generate a summary of this article
Listen to this article
Beta

Dr Reddy’s CEO tells Scrip in an interview that it isn’t business as usual, in general, in the US, where it is refining its proprietary products strategy to focus on ‘bigger assets’ in the backdrop of the payer environment there. The Indian company is, however, upbeat on plans for China.

GV Prasad
DR REDDY'S CEO G V PRASAD

Dr. Reddy's Laboratories Ltd. (DRL) continues to chisel and recalibrate its operations in the backdrop of a tough business environment in key markets like the US, but the Indian firm also expects to put the pedal to the metal in China, a market where it has had a long-standing base.(Also see "Big Cost Cuts At Dr Reddy’s, US Big Ticket Launch Progress Is Key" - Scrip, 27 July, 2018.)(Also see "India Pharma Firms Eye China, Dr Reddy’s Sees ‘Great Opportunity’ There" - Scrip, 29 October, 2018.)

In an interview with Scrip at the sidelines of the recently concluded India Pharmaceutical Forum in Mumbai, DRL’s co-chair and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains